Phase I study of bi-weekly <i>nab</i>-paclitaxel and carboplatin with concurrent thoracic radiotherapy for locally advanced non-small cell lung cancer.

Hasegawa, Yukihiro; Miura, Dai; Ota, Tomohiro; Yokouchi, Junichi

doi:10.1200/jco.2015.33.15_suppl.7529

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recently conducted phase I trial of this combination administered bi-weekly with concurrent thoracic radiation followed by 2 cycles of full dose nab-P and carboplatin reported acceptable safety profile with most common DLTs being pneumonitis, leukopenia, and treatment delays [19]. It has been suggested that this regimen may be more active in patients with squamous cell histology due to higher overall response rates reported.…”

Section: Newer Chemotherapeutic Agentsmentioning

confidence: 96%

Locally Advanced Non-Small Cell Lung Cancer: Optimal Chemotherapeutic Agents and Duration

Mamdani

Jalal

Hanna

2015

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality in the USA. The treatment of locally advanced NSCLC (LA-NSCLC) is challenging and must be individualized. For patients with completely resected stage III NSCLC, adjuvant cisplatin-based chemotherapy for 4 cycles is recommended. For patients with inoperable or unresectable stage III NSCLC, chemoradiation is the preferred treatment. Patients with a good performance status, minimal or no weight loss, and adequate pulmonary function should be offered concurrent chemoradiation. The optimal chemotherapeutic agents to be used concurrently with radiation remain undefined. In the USA, cisplatin plus etoposide or carboplatin plus paclitaxel are the most commonly used regimens. In addition, the optimal duration of therapy remains undefined, including the role of consolidation chemotherapy. Thus far, randomized phase III trials have failed to identify a survival advantage for administering chemotherapy beyond that delivered during radiation therapy. Molecularly targeted agents, angiogenesis inhibitors, and immunotherapy have a defined role for patients with metastatic disease. The role, if any, of these new classes of agents is undergoing investigation for patients with earlier stage disease, including stage III disease.

show abstract

Section: Newer Chemotherapeutic Agentsmentioning

confidence: 96%

Locally Advanced Non-Small Cell Lung Cancer: Optimal Chemotherapeutic Agents and Duration

Mamdani

Jalal

Hanna

2015

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

show abstract

Phase I study of nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in patients with locally advanced non-small cell lung cancer

Kaira

Tomizawa

Imai³

et al. 2016

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

show abstract

Application of nano-radiosensitizers in non-small cell lung cancer

Hu,

Pang

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

Radiotherapy stands as a cornerstone in the treatment of numerous malignant tumors, including non-small cell lung cancer. However, the critical challenge of amplifying the tumoricidal effectiveness of radiotherapy while minimizing collateral damage to healthy tissues remains an area of significant research interest. Radiosensitizers, by methods such as amplifying DNA damage and fostering the creation of free radicals, play a pivotal role in enhancing the destructive impact of radiotherapy on tumors. Over recent decades, nano-dimensional radiosensitizers have emerged as a notable advancement. Their mechanisms include cell cycle arrest in the G2/M phase, combating tumor hypoxia, and others, thereby enhancing the efficacy of radiotherapy. This review delves into the evolving landscape of nanomaterials used for radiosensitization in non-small cell lung cancer. It provides insights into the current research progress and critically examines the challenges and future prospects within this burgeoning field.

show abstract

Phase I study of bi-weekly nab-paclitaxel and carboplatin with concurrent thoracic radiotherapy for locally advanced non-small cell lung cancer.

Cited by 3 publications

References 0 publications

Locally Advanced Non-Small Cell Lung Cancer: Optimal Chemotherapeutic Agents and Duration

Locally Advanced Non-Small Cell Lung Cancer: Optimal Chemotherapeutic Agents and Duration

Phase I study of nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in patients with locally advanced non-small cell lung cancer

Application of nano-radiosensitizers in non-small cell lung cancer

Contact Info

Product

Resources

About